Lumida
/JYNT
⌘K
Joint Corp

Joint Corp

JYNT
$7.85USD↓-2.24%-0.18 today

MARKET CAP

111.0M

P/E (TTM)

34.1x

FWD P/E

—

DAY RANGE

$8 – $8

52W RANGE

$8
$11

AI Summary

Stalk
Buy NowMedium

JYNT is in Stage 2 advancing, having built a clear higher‐highs/higher‐lows sequence off its May lows and trading above rising 9/21/50 EMAs on expanding volume. Active Lockout Rally and HH/HL patterns reinforce bullish continuation, while short‐term pullbacks into the EMAs are supported. Despite overbought signals and a declining 200 DMA overhead, timing conditions favor immediate participation to ride further upside momentum.

  • ↑Cash flow from operations jumped 152% YoY to $2.2M
  • ↑Re-franchising reduces company-owned clinics to three, lowering capital needs
  • ↓Same-store sales fell 2.8% in Q2, indicating demand headwinds
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

The Joint Corp. (NASDAQ: JYNT) operates a network of chiropractic clinics in the United States, utilizing a franchising model that promotes rapid growth and minimizes capital expenditure. The company is strategically evolving to focus on enhanced patient experiences and operational efficiencies, aligning with ongoing consumer trends in health and wellness. As a capital-light franchisor, The Joint is well-positioned to capture opportunities in the burgeoning wellness market, although it faces pressure in terms of comp sales performance.

Bull says

  • ↑Cash flow from operations jumped 152% YoY to $2.2M
  • ↑Re-franchising reduces company-owned clinics to three, lowering capital needs
  • ↑Fiscal ’26 guidance: $519M–$552M system sales; $12.5M–$13.5M adj. EBITDA
  • ↑Patient retention hit five-year high via flexible membership options
  • ↑Revenue up 14% YoY to $15.2M; net income grew from $0.09M to $0.65M
  • ↑High earnings revisions and strong institutional ownership signal optimism

Bear says

  • ↓Same-store sales fell 2.8% in Q2, indicating demand headwinds
  • ↓Negative profitability score signals challenges converting revenue into profit
  • ↓Marketing expenses surged 40% YoY to $4.9M, pressuring margins
  • ↓Re-franchising execution risks persist—lease assignments may delay transfers
  • ↓Low earnings yield and high short interest reflect investor skepticism
  • ↓Size and book-to-price factors suggest competitive and valuation risks

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-09-2025bullish

Transcript signals

Bull points

  • System-wide sales for all clinics opened for any amount of time increased to $126.3 million, up 9%.
  • System-wide comp sales for all clinics opened 13 months increased 3%.
  • We began 2024 with a vision to be the champions of chiropractic and we focused on increasing new patient counts, improving existing patient engagement and positioning to refranchise the vast majority of our corporate portfolio. And we're making solid progress.

Bear points

  • System-wide comp sales for mature clinics opened 48 months or more decreased 3%.
Read full transcript analysis ›